Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MCHR1 | Q99705 | 4/20 | 0.43 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | FGFR1 | P11362 | 4/20 | 0.41 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.41 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.40 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.40 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4235464 | 0.97 | MCHR1 (0.44) | MCHR1MCHR2HRH3NAMPTFGFR1 | |
| SCHEMBL4235491 | 0.90 | HRH3 (0.48) | MCHR1MCHR2HRH3NAMPTSMN1; SMN2 | |
| SCHEMBL4233415 | 0.89 | MCHR1 (0.50) | MCHR1MCHR2HRH3FGFR1SMN1; SMN2 | |
| SCHEMBL4232252 | 0.87 | HRH3 (0.42) | MCHR1HRH3NAMPT | |
| SCHEMBL4233635 | 0.87 | HRH3 (0.42) | MCHR1HRH3NAMPTFGFR1SMN1; SMN2 | |
| SCHEMBL4231873 | 0.86 | CHRM3 (0.43) | MCHR1HRH3NAMPTADRA1DADRA1A | |
| SCHEMBL4236281 | 0.85 | TAS1R3 (0.45) | MCHR1MCHR2HRH3NAMPTHTR4 | |
| SCHEMBL4238075 | 0.85 | HRH3 (0.44) | HRH3NAMPTSMN1; SMN2 | |
| SCHEMBL4237921 | 0.84 | CCR3 (0.41) | HRH3NAMPTFGFR1 | |
| SCHEMBL4236380 | 0.84 | HRH3 (0.47) | HRH3NAMPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | claimed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MCHR1 47/4885MCHR2 30/4885HRH3 210/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.